HeartBeam (HeartBeam) Momentum Rank : 0 (As of May. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is HeartBeam Momentum Rank?

HeartBeam has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

HeartBeam Momentum Rank Related Terms

Thank you for viewing the detailed overview of HeartBeam's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

HeartBeam (HeartBeam) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050

Website

https://www.heartbeam.com

HeartBeam Inc is a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Its initial focus is providing diagnostic data to help physicians with the care management of patients with cardiovascular disease.

Executives

Urioste George De	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen	officer: Chief Technology Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno	officer: President	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein	officer: Chief Financial Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel	officer: Chief Operating Officer	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard M Ferrari	director, officer: Exec Chm of the BOD	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic	10 percent owner, officer: Chief Executive Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink	director	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt	officer: Chief Business Officer	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050